Zambon Launches Xadago(R) (Safinamide) in the U.K. for Patients with Mid- to Late-Stage Parkinson’s Disease

Zambon today announces the availability in the U.K. of Xadago® (safinamide) for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as an add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other Parki... Biopharmaceuticals, Neurology, Product LaunchNewron Pharmaceuticals, Zambon, Xadago, Parkinson’s disease

Source: HSMN NewsFeed - May 23, 2016 Category: Pharmaceuticals Source Type: news